Performing Virus Clearance Studies With Retroviral-Like Particles: Updated Guidance

For decades, demonstrating viral clearance in CHO-based biomanufacturing required labor-intensive live virus studies within specialized BSL-2 facilities. This traditional path often introduced significant logistical bottlenecks, high costs, and a heavy reliance on third-party contract research organizations. However, the adoption of the ICH Q5A(R2) guidelines marks a pivotal regulatory shift. Manufacturers can now utilize non-infectious, retroviral-like particles to validate process steps for late-stage biopharmaceuticals.

By integrating RVLP quantification into internal workflows, teams can generate highly correlative data to traditional models like XMuLV without the associated biosafety risks. This approach bolsters existing process knowledge and allows for high-throughput, automated analysis in-house. Embracing these surrogates not only aligns with updated regulatory expectations but also accelerates the timeline from process development to clinical application. Explore the breakdown of RVLP suitability and implementation strategies in the full article.